CARDIFF ONCOLOGY, INC. Capital Expenditures Incurred but Not yet Paid
CARDIFF ONCOLOGY, INC. (CRDF) reported Capital Expenditures Incurred but Not yet Paid of $2.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-11
- CARDIFF ONCOLOGY, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $2.00K.
- CARDIFF ONCOLOGY, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was -$896.00K.
- CARDIFF ONCOLOGY, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $902.00K.
- CARDIFF ONCOLOGY, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $744.00K.
- CARDIFF ONCOLOGY, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CARDIFF ONCOLOGY, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $16.00K, a 93.10% decline from fiscal 2022.
- CARDIFF ONCOLOGY, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $232.00K, a 3766.67% increase from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 6 month as first filed | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.00K 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | $744.00K 10-K · filed 2026-02-24 | ||||
| 2025-06-30 | -$896.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $6.00K 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | $902.00K 10-Q · filed 2026-05-14 | ||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-24 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $16.00K derived: sum of 3 quarters · filed 2024-08-08 | $0.00 derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | $16.00K derived: sum of 2 quarters · filed 2024-05-02 | $0.00 derived: sum of 3 quarters · filed 2024-05-02 | -$117.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | -$117.00K derived: sum of 3 quarters · filed 2024-08-08 | $16.00K 10-K · filed 2024-02-29 | |
| 2023-09-30 | -$16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$133.00K derived: sum of 2 quarters · filed 2024-08-08 | $0.00 10-Q · filed 2023-11-02 | -$23.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-06-30 | -$117.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $16.00K 10-Q · filed 2024-08-08 | -$7.00K derived: sum of 3 quarters · filed 2024-08-08 | -$208.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $133.00K 10-Q · filed 2024-05-02 | $110.00K derived: sum of 2 quarters · filed 2024-05-02 | -$91.00K derived: sum of 3 quarters · filed 2024-05-02 | $338.00K derived: sum of 4 quarters · filed 2024-05-02 | |
| 2022-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$224.00K derived: sum of 2 quarters · filed 2024-02-29 | $205.00K derived: sum of 3 quarters · filed 2024-02-29 | $232.00K 10-K · filed 2024-02-29 | |
| 2022-09-30 | -$201.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $228.00K derived: sum of 2 quarters · filed 2023-11-02 | $255.00K 10-Q · filed 2023-11-02 | $261.00K derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | $429.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $456.00K 10-Q · filed 2023-08-09 | $462.00K derived: sum of 3 quarters · filed 2023-08-09 | $435.00K derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $27.00K 10-Q · filed 2023-05-04 | $33.00K derived: sum of 2 quarters · filed 2023-05-04 | $6.00K derived: sum of 3 quarters · filed 2023-05-04 | $33.00K derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$21.00K derived: sum of 2 quarters · filed 2023-03-02 | $6.00K derived: sum of 3 quarters · filed 2023-03-02 | $6.00K 10-K · filed 2023-03-02 | |
| 2021-09-30 | -$27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $27.00K 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 | ||||
| 2020-06-30 | $11.00K 10-Q · filed 2021-08-05 | $11.45K 10-Q · filed 2020-08-11 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |